An observational study in Gastric Carcinoma, sponsored by Henan Cancer Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-27.
Sponsored by Henan Cancer Hospital · Observational
The study was designed to evaluate the efficacy and safety of apatinib in the treatment of patients with gastric carcinoma.
The study is a real-world non-interventional retrospective study and will collect the original medical records of patients with gastric carcinoma treated with apatinib from 2015 to 2018 in Henan Cancer Hospital. Clinical data such as patient demographic, history of treatments, tumor biological characteristics and adverse events will be analyzed to evaluate the efficacy and safety of apatinib and explore the risk factors of prognosis in patients with gastric carcinoma.
6,738 studies on the registry are indexed under Carcinoma; 1,159 are open to participants now.
This study's enrollment of 270 is above the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →Henan Cancer Hospital is the lead sponsor of 228 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Chinese patients who were pathologically or cytologically diagnosed gastric carcinoma and treated by apatinib.
Exclusion Criteria:
Overall Survival
Overall Survival
Time frame: 2015-2018
Objective Response Rate
Objective Response Rate
Time frame: 2015-2018
Disease Control Rate
Disease Control Rate
Time frame: 2015-2018
Progression-Free Survival
Progression-Free Survival
Time frame: 2015-2018
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Henan Cancer Hospital